Marsh & McLennan rose 5.5% last week, outpacing the median 2.9% gain for its closest insurance brokerage peers. BMO Capital's upgrade to Outperform, with a new $230 target, lands as short interest climbs to its highest level in two months. Michael Zaremski at BMO raised his rating from Market Perform to Outperform on 3 November, lifting his target from $204 to…
MRSH: BMO upgrades to Outperform, raises target to $230 from $204, implying 12% upside to price target.
Key data as of 10 Nov 2026
MRSH: BMO upgrades to Outperform, raises target to $230 from $204, implying 12% upside to price target.
Marsh & McLennan heads into its October 22 earnings date having already posted a Q3 result that sent the stock sharply higher, and the question now is whether the post-print rally has reset the debate or simply papered…
Marsh & McLennan enters its July 16 earnings print with one signal that has shifted materially since the prior note: options positioning has turned notably more defensive, even as the analyst debate and borrow market…
Options traders have shifted decisively toward calls on MRSH. The put-call ratio has dropped to 0.51 — nearly 1.6 standard deviations below its 20-day average of 0.62. That's close to a 52-week low of 0.49. It is the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MRSH — free to start on ORTEX.
Sign up for free →Open MRSH on ORTEX